加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.7509
−US$0.0481 · -6.02%
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
前收盘价
US$0.7509
−US$0.0481 · -6.02%
盘后
US$0.753
+US$0.0021 · +0.28%
10月12日 19:43 ET
盘中时间采用ET。市场数据可能有所延迟。
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
日内区间
当前US$0.7509
52周区间
当前US$0.7509
盘中时间采用ET。市场数据可能有所延迟。
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
日内区间
当前US$0.7509
52周区间
当前US$0.7509
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 163.3万 USD | 102.8万 USD | — | — | 271.7万 USD |
| 销货成本 | 90万 USD | — | 82.2万 USD | — | — |
| 毛利 | 73.3万 USD | 102.8万 USD | −82.2万 USD | — | 271.7万 USD |
| 研究与开发 | 2020.5万 USD | 2668.2万 USD | 3962.4万 USD | 3660.7万 USD | 2648.2万 USD |
| 销售、一般及管理费用 | 1973.8万 USD | 2394.6万 USD | 2647.5万 USD | 2684.4万 USD | 2783.4万 USD |
| 营业费用 | 3904.3万 USD | 5434.2万 USD | 6527.7万 USD | 6345.1万 USD | 5431.6万 USD |
| 利息收入 | 82.7万 USD | 176.3万 USD | 330.1万 USD | 124.8万 USD | 8.9万 USD |
| 利息支出 | 289.1万 USD | 503.3万 USD | 508.5万 USD | 107.1万 USD | 46.6万 USD |
| 折旧和摊销 | 90万 USD | 102.8万 USD | 82.2万 USD | 54.8万 USD | 49.7万 USD |
| 营业利润 | −3831万 USD | −5331.4万 USD | −6609.9万 USD | −6345.1万 USD | −5159.9万 USD |
| 净利润 | −2967.3万 USD | −3001.8万 USD | −3397万 USD | −3058.8万 USD | −833.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.67
上涨空间 1986.83%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI311.36万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF71.28万0.00%954亿 USD0.05%US$233.52-0.63%
Invesco Nasdaq Biotechnology ETFIBBQ6627.710.01%1.12亿 USD0.19%US$34.2482-1.07%
ProShares Ultra Nasdaq BiotechnologyBIB3329.490.00%9138.97万 USD1.19%US$108.79-1.90%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
